0001179110-20-012241.txt : 20201228 0001179110-20-012241.hdr.sgml : 20201228 20201228162313 ACCESSION NUMBER: 0001179110-20-012241 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201224 FILED AS OF DATE: 20201228 DATE AS OF CHANGE: 20201228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goldberg Mark Alan CENTRAL INDEX KEY: 0001532475 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 201418600 MAIL ADDRESS: STREET 1: 128 SPRING STREET, SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-12-24 0 0001597264 Blueprint Medicines Corp BPMC 0001532475 Goldberg Mark Alan C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2020-12-24 4 M 0 5455 28.15 A 9017 D Common Stock 2020-12-24 4 S 0 5455 125.00 D 3562 D Stock Option (Right to Buy) 28.15 2020-12-24 4 M 0 5455 0 D 2025-06-25 Common Stock 5455 0 D Effected pursuant to a trading plan adopted on August 5, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option was granted on June 25, 2015 and is fully vested as of the date hereof. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-12-28